Get startedLog in
    Picture of Kiniksa Pharmaceuticals International logo

    KNSA — Kiniksa Pharmaceuticals International News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: FDA Approves Arcalyst Injection To Treat Recurrent Pericarditis, Reduce Risk Of Recurrence

    Picture of Kiniksa Pharmaceuticals International logoKiniksa Pharmaceuticals International
    18/03/2021 22:15
    March 18 (Reuters) - 
    * FDA SAYS APPROVED ARCALYST INJECTION TO TREAT RECURRENT
PERICARDITIS, REDUCE RISK OF RECURRENCE IN ADULTS & CHILDREN 12
YEARS AND OLDER
    * FDA SAYS GRANTED APPROVAL OF ARCALYST TO KINIKSA
PHARMACEUTICALS
(UK) LTD

Source text: (https://bit.ly/3eTdc7W)

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kiniksa Pharmaceuticals International

    See all news